FILE PHOTO: Illustration of products are pictured from Qiagen, the diagnostics company which has agreed an $11.5 billion takeover deal with U.S-based Thermo Fisher in this picture illustration obtained by Reuters March 3, 2020. Qiagen/Handout via REUTERS
FRANKFURT/COPENHAGEN (Reuters) - Germany's Qiagen, a leading genetic testing supplier, on Thursday warned against re-engineering standard tests to monitor for new variants of the coronavirus, saying the more onerous decoding of the entire viral genome was the best method.
Scientists believe more contagious variants have fuelled a surge in global coronavirus cases that have exceeded 90 million, and nations are racing to procure vaccines and tighten lockdown measures.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
